Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM

Recruiting
Written By Sustainable Digital

First trial using a triple combination for WM in the US

Sites: Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Colorado Blood Cancer Institute, UT Southwestern

Accrual status: 55 of 55 patients (potential for additional patients, pending)

Sustainable Digital

Digital Communication services, including website design, search engine optimization, social media, and content creation for nonprofit organizations, consultants, and creative entrepreneurs.

http://www.sustainabledigital.com
Previous

Loncastuximab tesirine in previously treated WM
Next

Epcoritamab in previously treated WM